In This Story NVO -2.04% LLY -3.17% The use of GLP-1 meds — made popular by Ozempic ( NVO -2.04% ) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion. Suggested Reading 5 states where EU tariffs could be less painful Job cuts, inflation, and lowered GDP forecast is a recipe for stagflation, asset manager says Trump's planned 'reciprocal' tariffs will take effect 'immediately,' White House says Costco's

Tag-uri: Inflatie